Enobosarm is under clinical development by Veru and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase III drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Enobosarm’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Enobosarm (Ostarine, GTx-024, MK-2866) is under development for the treatment of estrogen receptor positive/androgen receptor-positive and HER2 negative breast cancer. It is a selective androgen receptor modulator (SARM). It is a new chemical entity and is administered by oral route. It was also under development for the prevention of muscle wasting (cancer cachexia), sarcopenia and stress urinary incontinence (SUI) and duchenne muscular dystrophy androgen receptor-positive triple negative breast cancer.
Veru is a biopharmaceutical company that develop novel medicines for the management of breast cancer and prostate cancer. The company is headquartered in United States.
For a complete picture of Enobosarm’s drug-specific PTSR and LoA scores, buy the report here.